Leerink Partners on Viridian Therapeutic (VRDN): 'encouraged' by response rate, but efficacy below investor expectations
Tweet Send to a Friend
Leerink Partners analyst Thomas Smith reiterated an Outperform rating and $50.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
